Compare SE & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | ALNY |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0B | 60.1B |
| IPO Year | 2017 | 2004 |
| Metric | SE | ALNY |
|---|---|---|
| Price | $124.67 | $391.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 27 |
| Target Price | $191.91 | ★ $484.39 |
| AVG Volume (30 Days) | ★ 5.1M | 1.1M |
| Earning Date | 11-11-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1416.22 | N/A |
| EPS | ★ 2.29 | 0.33 |
| Revenue | ★ $21,037,037,000.00 | $3,210,070,000.00 |
| Revenue This Year | $37.28 | $69.60 |
| Revenue Next Year | $24.30 | $42.67 |
| P/E Ratio | ★ $54.48 | $1,205.23 |
| Revenue Growth | 35.84 | ★ 53.24 |
| 52 Week Low | $99.50 | $205.87 |
| 52 Week High | $199.30 | $495.55 |
| Indicator | SE | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 31.31 |
| Support Level | $123.16 | $387.03 |
| Resistance Level | $129.10 | $479.79 |
| Average True Range (ATR) | 4.58 | 16.69 |
| MACD | -0.09 | -6.48 |
| Stochastic Oscillator | 18.99 | 4.58 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2025, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.1% of voting power. Tencent owned 18.5% of issued shares with no voting power.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.